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Objective: We investigated the burden of chronic kidney disease (CKD) among patients with 
severe mental illness (SMI).
Methods: We identified patients with SMI among all those aged 25–74 registered in the UK 
Clinical Practice Research Datalink as on March 31, 2014. We compared the prevalence of CKD 
(two measurements of estimated glomerular filtration rate <60 mL/min/1.73 m2 for ≥3 months) 
and renal replacement therapy between patients with and without SMI. For patients with and 
without a history of lithium prescription separately, we used logistic regression to examine the 
association between SMI and CKD, adjusting for demographics, lifestyle characteristics, and 
known CKD risk factors.
Results: The CKD prevalence was 14.6% among patients with SMI and a history of lithium 
prescription (n = 4,295), 3.3% among patients with SMI and no history of lithium prescription 
(n = 24,101), and 2.1% among patients without SMI (n = 2,387,988; P < 0.001). The prevalence 
of renal replacement therapy was 0.23%, 0.15%, and 0.11%, respectively (P = 0.012). Compared 
to patients without SMI, the fully adjusted odds ratio for CKD was 6.49 (95% CI 5.84–7.21) for 
patients with SMI and a history of lithium prescription and 1.45 (95% CI 1.34–1.58) for patients 
with SMI and no history of lithium prescription. The higher prevalence of CKD in patients with SMI 
may, in part, be explained by more frequent blood testing as compared to the general population.
Conclusion: CKD is identified more commonly among patients with SMI than in the general 
population.
Keywords: severe mental illness, schizophrenia, bipolar disorder, chronic kidney disease, lithium
Introduction
People with severe mental illness (SMI), including schizophrenia, bipolar disorder, 
and other nonorganic psychotic illnesses, are known to have shorter life expectancy, 
by ~10–20 years, than the general population.1–6 Their premature death is attributed not 
only to suicide and accident but also to physical illnesses – especially cardiovascular 
diseases such as coronary heart disease and stroke.5–9 The high rate of cardiovascular 
deaths in patients with SMI has been attributed to the high prevalence of lifestyle-
related conditions (eg, smoking and obesity),10–13 suboptimal screening/assessment 
of cardiovascular risks,14,15 and suboptimal management of underlying diseases (eg, 
hypertension, diabetes, dyslipidemia).16–18
Chronic kidney disease (CKD) – the continuous presence of kidney damage 
and/or decreased level of kidney function19 – is independently associated with 
increased risk of death, cardiovascular events, and all-cause hospitalization.20 CKD 
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can progress to end-stage renal disease (ESRD) requiring 
renal replacement therapy (RRT), a substantial burden for 
both – quality of life of patients and health budgets. The UK 
National Institute for Health and Care Excellence guidance 
for CKD recommends early identification and appropriate 
management of CKD.21
People with SMI have an increased prevalence of several 
risk factors for CKD, including smoking and diabetes.13,16,22 
Moreover, patients with SMI may be treated with lithium, 
which is associated with the development of CKD.23,24 
However, there has been limited research investigating the 
prevalence of, and risk factors for, CKD in people with 
SMI.13,25,26 In the UK, primary care plays an important role 
in the management of physical health conditions in people 
with SMI. As part of the Quality and Outcomes Framework 
(QOF), there have been recent financial incentives for general 
practitioners (GPs) to undertake physical health checks in 
people with SMI.27 However, it is unclear whether CKD in 
patients with SMI is appropriately recognized and managed 
by GPs.
Therefore, we used a UK primary care database to: 1) 
compare the prevalence of CKD and RRT among patients 
with SMI (with and without a history of lithium use) and 
those without SMI; 2) investigate whether there is an inde-
pendent association between SMI and CKD after adjusting 
for known CKD risk factors; and 3) compare the recognition 
and management of CKD between CKD patients with and 
without SMI.
Materials and methods
Data source
The Clinical Practice Research Datalink (CPRD) is an 
observational data and interventional research service pro-
vided by the National Health Service. Around 98% of the 
UK population are registered with a primary care practice. 
Currently, >650 general practices contribute data conforming 
to quality control standards to the CPRD, including ~ 7% of 
the UK population. The included practices are representative 
of the UK general population in terms of age and sex.28 The 
database includes the following data: patient demograph-
ics, diagnoses based on Read codes (a hierarchical coding 
system), prescriptions based on British National Formulary 
codes, laboratory test results, and referrals made by GPs. 
Ethical approval for this study was obtained from the Inde-
pendent Scientific Advisory Committee of CPRD (protocol 
no. 16_055). Informed consent was waived because data are 
anonymized for research purposes.
study population
Our study population included all people, aged 25–74 years, 
registered in the CPRD for at least 1 year as on March 31, 
2014 (ie, the end of a financial or QOF year). We selected the 
25–74 age range because our preliminary analysis suggested 
that CKD and/or SMI were rare in people outside these param-
eters, thereby limiting the power for comparative prevalence 
analyses. To ensure that we had reliable measures of morbidity 
(to allow time for the recording of past medical history in 
newly registered patients), we required that all participants 
had at least 1 year of continuous registration in the CPRD.
Disease definition
We identified SMI using Read morbidity codes that have 
been validated in UK primary care data, with high sensitiv-
ity (91%), specificity (99.9%), and positive predictive value 
(91%).29 Patients with SMI were further classified as those 
with and without any record of lithium prescription in the 
period between the CPRD registration and March 31, 2014. 
We excluded patients who had been prescribed lithium with-
out recorded SMI from the general population comparison 
group because the indication for treatment was not known.
Our definition of CKD was based on two measurements 
of estimated glomerular filtration rate <60 mL/min/1.73 m2 
separated by 3 months or longer,19 calculated from serum 
creatinine records in the CPRD in the past 5 years, using the 
Chronic Kidney Disease Epidemiology  Collaboration equa-
tion.30 RRT was characterized on the basis of diagnosis codes 
suggesting hemodialysis, peritoneal dialysis, or kidney trans-
plantation. Previous research has shown that the prevalence of 
estimated glomerular filtration rate <60 mL/min/1.73 m2 and 
RRT in the CPRD is similar to that estimated in a nationally 
representative population survey (Health Survey for England) 
and disease registry (UK Renal Registry), suggesting that 
most cases of CKD and RRT are captured in the CPRD.31
Covariate definition
We defined baseline characteristics of patients with and 
without SMI: age, sex, ethnicity, socioeconomic status (SES), 
country of the UK (ie, England, Northern Ireland, Scotland, 
and Wales) body mass index (BMI), smoking status, chronic 
diseases that are associated with CKD21 – diabetes, hyper-
tension, cardiovascular disease (ie, myocardial infarction, 
chronic heart failure, peripheral arterial disease, and stroke), 
urological disease (ie, vesicoureteral reflux, renal tract stone, 
and prostatic hypertrophy), systematic lupus erythematosus, 
and polycystic kidney disease – based on relevant diagnosis 
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codes. Based on previous studies using UK primary care 
data,32,33 we grouped patients with no record of ethnicity 
into those of white ethnicity. SES was assigned at the gen-
eral practice level using quintiles of the Index of Multiple 
Deprivation in each country of the UK.34 BMI and smoking 
status were based on the most recent records prior to the date 
of study inclusion (ie, March 31, 2014). For chronic diseases, 
if a diagnosis code was recorded for a patient during the 
period between CPRD registration and the study date, then 
that disease was regarded as being present.
Data analysis
We compared baseline characteristics and overall prevalence 
of CKD (including patients on RRT) among the three groups: 
patients with SMI with and without a history of lithium 
prescription as well as those without SMI, using chi-squared 
tests. We stratified CKD prevalence by age (using 10-year age 
bands) and sex. We estimated the prevalence of RRT among 
the three groups and compared it overall by chi-squared tests. 
Moreover, we compared the distribution of the most recent 
category of RRT modality (hemodialysis, peritoneal dialysis, 
or kidney transplantation) between patients with and without 
SMI using chi-squared tests.
Next, we carried out logistic regression analyses to exam-
ine the association between SMI (with and without a history 
of lithium use) and CKD. To understand which factors are 
more likely to explain the association between SMI and CKD, 
we adjusted step-by-step for age and sex, ethnicity, SES, BMI, 
smoking status, and chronic diseases associated with decline 
in kidney function (ie, diabetes, hypertension, cardiovascular 
disease, urological disease, systemic lupus erythematosus, 
and polycystic kidney disease).21 Patients with missing data of 
BMI and smoking status were excluded from the analysis. We 
took into account variations in coding and testing practices 
by different general practices through clustering by general 
practice in the logistic regression models.
Finally, we restricted analysis to patients with CKD who 
were not on RRT and compared the recognition and manage-
ment of CKD between patients with and without SMI. We 
used the QOF CKD indicators (QOF version 2013/14) as 
markers of the recognition and management of CKD in the 
UK primary care.27 We determined the proportion of CKD 
patients with and without SMI who had: 1) a record of a 
diagnostic code for CKD, using CKD codes listed in the QOF 
version 2013/14;35 2) the most recent blood pressure measure 
≤140/90 mmHg (recorded in the year before the date of the 
study); 3) urine test for proteinuria/albuminuria (including 
dipstick test) in the year before the date of the study; and 4) 
for those with hypertension and proteinuria (recorded any 
time between CPRD registration and study date), at least one 
prescription for a renin–angiotensin system antagonist in the 
past 3 months. In addition, because the National Institute for 
Health and Care Excellence guidance for cardiovascular dis-
ease recommends statins as primary prevention for all CKD 
patients regardless of serum cholesterol levels,36 we compared 
the proportion of CKD patients with and without SMI who 
had at least one prescription for a statin in the past 3 months.
All statistical analyses were conducted using Stata 14 
(Stata Corp, College Junction, TX, USA).
Results
Of the 2,418,730 people aged 25–74 years who were registered 
in the CPRD for >1 year on March 31, 2014, we identified 
28,396 (1.17%) patients with SMI, including 4,295 patients 
with a history of lithium prescription in the CPRD and 24,101 
without (Figure 1). In patients with SMI (both with and  without 
Figure 1 Flow chart showing identification of study participants.
Abbreviations: CPrD, Clinical Practice research Datalink; sMi, severe mental illness.
People aged 25–74 registered in the CPRD (for ≥1 year)
on March 31, 2014, N = 2,418,730
People without SMI diagnosis
N = 2,390,334
Patients with lithium
prescription in CPRD
N = 2,346
Patients without SMI diagnosis
(and no lithium use in CPRD)
N = 2,387,988
Patients with no history
of lithium use in CPRD
N = 24,101
Patients with history of
lithium use in CPRD
N = 4,295
People with SMI diagnosis
N = 28,396
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a previous lithium prescription) compared to those without, the 
SES was generally lower and the proportions of black ethnicity, 
obesity (BMI ≥30 kg/m2), and current smokers were higher. 
Diabetes, hypertension, and cardiovascular diseases were more 
common in patients with SMI, whereas the prevalence of other 
diseases (urological disease, systematic lupus erythematosus, 
and polycystic kidney disease) was similar between patients 
with and without SMI (Table 1).
Overall, the prevalence of CKD was 14.64% (629/4,295) 
in patients with SMI and history of lithium prescription, 
3.34% (805/24,101) in patients with SMI and no history 
of lithium prescription, and 2.09% (49,870/2,387,988) in 
patients without SMI (P < 0.001). The absolute difference 
in CKD prevalence among the three groups increased with 
age in both men and women (Figure 2). Moreover, there was 
evidence (P = 0.012) that the overall prevalence of RRT was 
higher in patients with SMI (0.23% [10/4, 295] and 0.15% 
[36/24, 101] in those with and without a history of lithium 
prescription, respectively) than those without SMI (0.11% 
[2,645/2,387,988]). There was strong evidence that the dis-
tribution of RRT modalities was different between patients 
with and without SMI (P = 0.001). In patients with SMI, 
50% (23/46) were receiving hemodialysis and 2% (1/46) 
peritoneal dialysis, and 48% (22/46) underwent kidney 
transplantation. However, in patients without SMI, the cor-
responding figures were 26% (700/2,645), 7% (194/2,645), 
and 66% (1,751/2,645).
The age–sex-adjusted odds ratio (OR) for CKD was 7.13 
(95% confidence interval [CI] 6.47–7.85) for patients with 
SMI and history of lithium use, and 1.69 (1.56–1.83) for 
those with SMI and no history of lithium use, compared to 
those without SMI. After adjusting for SES, BMI, smoking, 
and chronic diseases associated with CKD, the adjusted ORs 
decreased to 6.49 (5.84–7.21) and 1.45 (1.34–1.58) but were 
still significant in patients with SMI with and without previ-
ous lithium prescription, respectively (Table 2).
Among patients with biochemically defined CKD (not on 
RRT), a higher proportion of people with SMI had a recorded 
diagnosis of CKD (SMI 70.3%, without SMI 65.5%) and 
a recorded blood pressure ≤140/90 mmHg (SMI 80.1%, 
without SMI 75.6%; Table 3). However, a lower proportion 
of patients with SMI had recently been prescribed statins 
(SMI 50.5%, without SMI 59.0%).
Discussion
Main findings
We found that, in UK primary care, patients with SMI 
had a greater prevalence of CKD compared to the general 
 population. This was pronounced (6.5-fold increase) in 
patients with a history of lithium prescription, but there was 
a 1.5-fold increase in odds of CKD even among patients 
never known to be prescribed lithium and after adjustment 
for differences in known risk factors for CKD. In addition, 
patients with SMI had an increased prevalence of RRT and 
were more likely to be receiving hemodialysis as their modal-
ity than patients without SMI on RRT.
Strengths and limitations
There are several strengths of our study. There is likely to 
be a good recording of the diagnoses examined because GPs 
manage patients with SMI for their physical and mental health 
– with or without the support of psychiatrists in secondary 
care. In addition, the QOF – the reward and incentive pro-
gram for GPs – included both SMI and CKD during this time 
period.27 Moreover, the diagnosis of SMI has been validated 
at the individual level,29 and the prevalence estimates of 
CKD and RRT have been validated at the population level.31
However, we need to acknowledge several limitations. 
First, this is a cross-sectional study, in which temporal rela-
tionships cannot always be clarified. The majority of patients 
with SMI have developed symptoms by early adulthood,37 
whereas the prevalence of CKD starts to increase after age 
55.31 Therefore, it is unlikely that CKD precedes the onset of 
SMI. However, the interpretation of potential risk factors in 
the association between SMI and CKD requires caution. For 
example, cessation of smoking and lithium may be as a result 
of the development of CKD. Therefore, we did not differenti-
ate previous and current users in the regression models. Sec-
ond, a greater prevalence of CKD among patients with SMI 
may, in part, be influenced by surveillance or ascertainment 
bias. Patients with SMI take medications, such as lithium and 
other psychotropic drugs, which need regular monitoring. In 
addition, in 2013–2014, GPs were incentivized to monitor 
blood glucose and cholesterol levels for people with SMI; 
therefore, many patients would have had concurrent testing 
of renal function.38 In contrast, in the general population, cre-
atinine testing in primary care is not universal: in 2013–2014, 
this was recommended and incentivized only for people with 
known CKD risk factors.21,27 However, we have previously 
demonstrated that the prevalence of CKD identified in the 
CPRD was very similar to that seen in the Health Survey for 
England, a nationally representative survey of the general 
population.31 This suggests that most patients with CKD are 
captured by the current testing strategy in primary care, and 
the proportion of patients with unmeasured CKD in CPRD 
is small. Therefore, underascertainment of CKD in people 
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Table 1 Characteristics of patients by sMi diagnosis and history of lithium use
Characteristic Patients without 
SMI diagnosis  
N = 2,387,988
Patients with SMI diagnosis (N = 28,396)
Patients with no history of 
lithium use N = 24,101
Patients with history of 
lithium use N = 4,295
n (%) n (%) n (%)
Type of SMI diagnosis
schizophrenia – 9,134 (37.9) 448 (10.4)
Bipolar disorder – 5,881 (24.4) 3,374 (78.6)
Other nonorganic psychosis – 9,086 (37.7) 473 (11.0)
Age category (years)
25–34 468,602 (19.6) 3,654 (15.2) 242 (5.6)
35–44 503,405 (21.1) 5,475 (22.7) 688 (16.0)
45–54 571,325 (23.9) 6,361 (26.4) 1,187 (27.6)
55–64 456,457 (19.1) 4,844 (20.1) 1,209 (28.2)
65–74 388,199 (16.3) 3,767 (15.6) 969 (22.6)
sex (male) 1,193,218 (50.0) 13,183 (54.7) 1,761 (41.0)
Ethnicity
White/unrecorded* 2,232,403 (93.5) 22,051 (91.5) 4,184 (97.4)
Black 42,339 (1.8) 836 (3.5) 35 (0.8)
south asian 72,190 (3.0) 734 (3.1) 42 (1.0)
Other 41,056 (1.7) 480 (2.0) 34 (0.8)
Country
England 1,739,874 (72.9) 17,507 (72.6) 2,815 (65.5)
north ireland 92,714 (3.9) 931 (3.9) 234 (5.5)
scotland 307,936 (12.9) 3,084 (12.8) 765 (17.8)
Wales 247,464 (10.4) 2,579 (10.7) 481 (11.2)
Socioeconomic status
1 (least deprived) 468,867 (19.6) 3,463 (14.4) 856 (19.9)
2 496,229 (20.8) 4,295 (17.8) 864 (20.1)
3 483,617 (20.3) 4,706 (19.5) 833 (19.4)
4 508,424 (21.3) 6,084 (25.2) 948 (22.1)
5 (most deprived) 430,851 (18.0) 5,553 (23.0) 794 (18.5)
Body mass index (kg/m2)
<18.5 37,526 (1.6) 497 (2.1) 56 (1.3)
18.5 to <25 772,208 (32.3) 6,868 (28.5) 988 (23.0)
≥25 to <30 716,303 (30.0) 7,480 (31.0) 1,482 (34.5)
≥30 530,065 (22.2) 8,281 (34.4) 1,724 (40.1)
Missing data 331,886 (13.9) 975 (4.1) 45 (1.1)
Smoking status
nonsmoker 962,061 (40.3) 5,578 (23.1) 1,123 (26.2)
Current smoker 516,109 (21.6) 10,677 (44.3) 1,485 (34.6)
Ex-smoker 861,414 (36.1) 7,773 (32.3) 1,685 (39.2)
Missing data 48,404 (2.0) 73 (0.3) <5 (<0.1)
Chronic diseases associated with CKD
Diabetes mellitus 166,917 (7.0) 3,421 (14.2) 718 (16.7)
hypertension 682,868 (28.6) 8,826 (36.6) 2,138 (49.8)
Cardiovascular disease
Myocardial infarction 31,659 (1.3) 390 (1.6) 81 (1.9)
Chronic heart failure 10,997 (0.5) 192 (0.8) 38 (0.9)
Peripheral arterial disease 15,383 (0.6) 232 (1.0) 47 (1.1)
stroke 24,097 (1.0) 419 (1.7) 96 (2.2)
Urological disease
Vesicoureteral reflux 1,676 (0.1) 16 (0.1) 5 (0.1)
renal tract stone 30,665 (1.3) 266 (1.1) 41 (1.0)
Prostatic hypertrophy 40,855 (1.7) 379 (1.6) 105 (2.4)
Other
systemic lupus erythematosus 3,423 (0.1) 47 (0.2) 5 (0.1)
Polycystic kidney disease 1,980 (0.1) 22 (0.1) <5 (<0.1)
Note: *number of patients without recorded ethnicity was 1,141,478 (47.8%), 9,687 (40.2%), and 2,045 (47.6%), respectively.
Abbreviations: CKD, chronic kidney disease; sMi, severe mental illness.
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without SMI is unlikely to be a substantial contributor to our 
results. Third, RRT is a rare outcome: the incidence of RRT 
in the UK is ~100 per million population.39 Combined with 
the cross-sectional design, this meant that, despite the large 
sample size, the number of patients with SMI and RRT was 
limited (n = 46). Although there was a statistically significant 
difference in the prevalence of RRT between patients with 
and without SMI, more detailed comparison (eg, stratification 
Figure 2 Prevalence of CKD in patients with and without sMi by age in men and women.
Abbreviations: CKD, chronic kidney disease; sMi, severe mental illness.
CKD prevalence (%), men
5
10
15
20
25
30
35
0
25–34 35–44 45–54
Age (years)
55–64 65–74
5
10
15
20
25
30
35
0
25–34 35–44 45–54
Age (years)
55–64 65–74
CKD prevalence (%), women
SMI and history of lithium use
SMI and no history of lithium use
No SMI
Table 2 adjusted logistic regression analyses of the association between sMi and chronic kidney disease
Model Adjusted odds ratio (95% CI) for chronic kidney disease
Patients without SMI Patients with SMI and no 
history of lithium use
Patients with SMI and  
history of lithium use
Model 1: adjusted by age and sex 1 (ref) 1.69 (1.56–1.83) 7.13 (6.47–7.85)
Model 2: Model 1 + adjusted by ethnicity, country, and 
socioeconomic status
1 (ref) 1.65 (1.52–1.79) 7.13 (6.48–7.86)
Model 3: Model 2 + adjusted by smoking status 1 (ref) 1.60 (1.48–1.74) 6.91 (6.27–7.61)
Model 4: Model 3 + adjusted by body mass index 1 (ref) 1.53 (1.42–1.66) 6.44 (5.84–7.09)
Model 5: Model 4 + adjusted by diabetes 1 (ref) 1.42 (1.31–1.54) 6.23 (5.64–6.88)
Model 6: Model 5 + adjusted by other chronic diseases* 1 (ref) 1.45 (1.34–1.58) 6.49 (5.84–7.21)
Note: *Hypertension, cardiovascular disease (myocardial infarction, chronic heart failure, peripheral arterial disease, and stroke), urological disease (vesicoureteral reflux, 
renal tract stone, and prostatic hypertrophy), systematic lupus erythematosus, and polycystic kidney disease.
Abbreviations: CI, confidence interval; ref, reference; SMI, severe mental illness.
Table 3 recognition and management of CKD in CKD patients with and without sMi
Indicator of CKD recognition/management Patients with biochemically defined CKD (not on RRT)
With SMI N = 1,388,
n (%)
Without SMI N = 47,225,
n (%)
1) recorded diagnosis of CKD 976 (70.3) 30,922 (65.5)
2) Most recent blood pressure ≤140/90 mmhg 1,112 (80.1) 35,705 (75.6)
3)  Prescription of renin–angiotensin system antagonists (among patients with 
hypertension and proteinuria diagnoses), numerator/denominator (%)
52/66 (78.8) 2,905/3,428 (84.7)
4) Proteinuria/albuminuria testing in the past year 421 (30.3) 15,263 (32.3)
5) Prescription of statins 701 (50.5) 27,853 (59.0)
Abbreviations: CKD, chronic kidney disease; rrT, renal replacement therapy; sMi, severe mental illness.
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by age and sex) or analysis of risk factors for RRT was not 
possible with these numbers. Finally, our adjusted analyses 
suggested that differences in the prevalence of risk factors 
between patients with and without SMI did not completely 
explain the association between SMI and CKD. This finding 
may be due to additional unconsidered risk factors, differ-
ences in patient management, or residual confounding. For 
example, antipsychotics used for SMI have been suggested 
to cause acute kidney injury,40,41 which is a known risk fac-
tor for subsequent CKD.21 Furthermore, insufficient control 
– or later initiation – of treatment for the CKD risk factors 
(eg, high blood pressure, diabetes, and obesity) may lead to 
higher incidence of CKD in the SMI population; however, 
this information could not be adequately captured in this 
cross-sectional study. Using recorded CPRD diagnoses, 
moreover, means that the misclassification or underiden-
tification of disease status (eg, diabetes and heart failure) 
is possible. We did not have any information on the use of 
lithium before the CPRD registration and, therefore, some 
patients may have been wrongly classified as not having used 
lithium. This also meant that we were unable to examine the 
association between the length or cumulative dose of lithium 
prescription and CKD.
Comparison with other studies
Few studies have examined the prevalence of CKD in the pop-
ulation with SMI. A small cross-sectional study in London, 
UK, found a similar relative difference in CKD prevalence 
between those with and without SMI despite a less accurate 
CKD definition than in the present study.13 A Taiwanese 
cohort study showed that people with schizophrenia are more 
likely to develop CKD,25 whereas a cross-sectional analysis 
of Scottish primary care demonstrated that people with 
bipolar disorder had a higher prevalence of CKD than people 
without the condition.18 Several studies have focused on the 
prevalence or incidence of CKD in patients using lithium. 
A Swedish cohort study showed that the prevalence of CKD 
(defined as serum creatinine level >150 μmol/L) and ESRD 
requiring RRT was higher in people ever exposed to lithium 
than in the general population,42 whereas a Danish cohort 
study also showed that lithium prescription was associated 
with an increased rate of CKD diagnosis.26
The relative risk of lithium use for the prevalence of 
CKD in our study (the fully adjusted OR of 6.5) was larger 
than those estimated in previous studies: the adjusted hazard 
ratio by lithium for CKD was nearly 2 in a cohort study in 
Oxford, UK,43 and around 3 in the Danish cohort study.26 
These differences can be explained by the different nature of 
the study population in each study. We compared people with 
lithium prescription for SMI and those without SMI in the 
general population, whereas the UK cohort study compared 
those with and without lithium use among people with at 
least two blood samplings in hospitals in Oxford,43 and the 
Danish study estimated the risk of lithium prescription in the 
population with a single manic episode or bipolar disorder.26 
Therefore, our comparison group is healthier than in the other 
studies, although again, ascertainment bias may play a role 
to some extent in our study.
The management of CKD includes prevention of car-
diovascular events. Several previous studies have focused 
on inequalities in medication use for cardiovascular risk 
between patients with and without SMI. Studies from the 
UK showed that statin prescribing is lower in patients with 
schizophrenia and bipolar disorder than in the general popula-
tion, although their cardiovascular risks are higher.16,18 A US 
study suggests that prescribing of renin–angiotensin system 
antagonists and statins is suboptimal in patients with SMI 
and type 2 diabetes.17 Our finding of lower prescribing of 
statins among patients with SMI and CKD, compared to the 
general population, are consistent with these earlier studies.
Explanation of findings and clinical 
relevance
CKD is strongly and independently associated with mortality 
and cardiovascular risk.20 Therefore, the higher prevalence 
of CKD we have established may contribute to the known 
shorter life expectancy in people with SMI. Moreover, we 
have shown that the difference in CKD prevalence between 
patients with and without SMI increased with age. It is pos-
sible that progressive accumulation and biological effect of 
CKD risk factors in patients with SMI (eg, obesity, smoking, 
and diabetes) leads to an increased incidence of CKD at an 
older age.
We have confirmed a higher burden of CKD risk factors 
among patients with SMI, and adjustment for these partially 
explained the association between SMI and CKD. However, 
many questions about the cause of the higher prevalence of 
CKD remain unanswered. Our snapshot of GP’s management 
of patients with SMI suggests that CKD is more commonly 
coded as a diagnosis than in the general population. The 
extent to which this is driven by incentivized management 
schemes and regular testing of renal function for patients with 
SMI – particularly those prescribed lithium and other psy-
chotropic medications – is unknown. Whereas blood  pressure 
appeared better controlled among SMI patients, this may 
reflect different underlying renal pathologies associated with 
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lower rates of hypertension (eg, interstitial nephritis related 
to lithium). Other aspects of management – proteinuria test-
ing as well as prescription of statins and renin–angiotensin 
system antagonists – were lower among patients with SMI.
Of greatest concern is our finding of the substantial 
increase in the prevalence of RRT among patients with SMI. 
The development of ESRD results in markedly reduced qual-
ity of life and psychological stress. Renal transplantation is 
associated with better quality of life and, possibly, longer 
survival.44 However, our results showed that the proportion 
of patients receiving kidney transplantation was substantially 
lower in patients with SMI than those without. It is important 
to understand why this difference arises and ensure that there 
are no inappropriate barriers to the consideration for renal 
transplantation for people with SMI.
Conclusion
We found that the prevalence of CKD and RRT was sub-
stantially higher in patients with SMI as compared to the 
general population. There was a greater burden of risk 
factors among patients with SMI, but these did not fully 
explain the increased prevalence of CKD. Further informa-
tion about the management of CKD in SMI patients such as 
referral to specialist care and management of comorbidities 
is needed to identify opportunities for prevention of CKD 
and its progression.
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